ACTIVE

C.E.R. - CLINICAL ENGINEERING & RESEARCH

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result
197,4 k €
+22,0 %over 1 year
Gross margin
1,2 M €
+4,1 %over 1 year
Equity
13,3 M €
-0,8 %over 1 year
Workforce
2,0 ETP
+100,0 %over 1 year

Identity

Source · BCE/KBO

C.E.R. - CLINICAL ENGINEERING & RESEARCH is a Private limited company incorporated in 1983. Its main activity is: Activities of holding companies. Its registered office is in Sint-Martens-Latem. It employs on average 2,0 ETP workers (FTE).

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0425.363.905
Incorporation
20/12/1983
Legal form
Private limited company
Registered office
Bogaertstraat 24
9830 Sint-Martens-Latem · FlandreSee on map
Contributed capital
123 946,76 €
Latest accounts
31/12/2025
Average workforce
2,0 ETP
Joint committees (4)
  • 100
  • 146
  • 218
  • 323
Signals
ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debts

Financials

Source · NBB, 10 filings

Trend over 10 financial years

20252024201320122011
Income statement
Gross margin1,2 M €1,2 M €1,5 M €1,3 M €923,9 k €
EBITDA1 M €965,1 k €1,3 M €1,2 M €1,1 M €
Operating result264,5 k €238 k €721,1 k €558,6 k €457,6 k €
Net result197,4 k €161,8 k €261,5 k €62,2 k €333,5 k €
Balance sheet
Equity13,3 M €13,5 M €6 M €5,8 M €5,7 M €
Total assets17,1 M €17,6 M €17,1 M €15,4 M €15 M €
Cash529,1 k €248 k €8,9 k €343,3 k €2,6 M €
Debts3,6 M €4 M €10,7 M €9,3 M €9 M €
Other
Workforce2,0 ETP1,0 ETP2,7 ETP2,7 ETP2,7 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 5 M€ and 10 M€
See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

2 active · 2 ended

Active mandates

Jan RUYSSCHAERT

Director

Active
Lieve VANHOUTEGHEM

Director

Active

Ended mandates

Jan RUYSSCHAERT

Manager

Ended
Lieve VANHOUTEGHEM

Manager

Ended

Other companies at this address

Bogaertstraat 24 9830 Sint-Martens-Latem
CompanyCBE no.
ART STUDIO L&J● Active
0741.845.508
BISMO● Active
0720.551.830
DE BOGAARD● Active
0742.842.331
L&J Invest● Active
0743.775.709
L&J - label● Active
0553.681.839

Full financial information

Source · NBB
202520242013201220112010
Type of accountAbridged modelAbridged modelAbridged modelAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202501/01/202401/01/201301/01/201201/01/201101/01/2010
Closing of the financial year31/12/202531/12/202431/12/201331/12/201231/12/201131/12/2010
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date26/06/202608/07/202529/07/201430/07/201329/08/201219/08/2011
General meeting30/05/202631/05/202531/05/201425/05/201326/05/201228/05/2011
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for 7 days

Annual accounts filings

Source · NBB, 10 filings
ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202530/05/202626/06/2026DutchPDF
Abridged model31/12/202431/05/202508/07/2025DutchPDF
Abridged model31/12/201331/05/201429/07/2014DutchPDF
Abridged model31/12/201225/05/201330/07/2013DutchPDF
Abridged model31/12/201126/05/201229/08/2012DutchPDF
Abridged model31/12/201028/05/201119/08/2011DutchPDF
Abridged model31/12/200929/05/201027/08/2010DutchPDF
Abridged model31/12/200830/05/200909/06/2009DutchPDF
Abridged model31/12/200731/05/200807/08/2008DutchPDF
Abridged model31/12/200626/05/200704/07/2007DutchPDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 5 M€ and 10 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

2 active · 2 ended

Active mandates

Jan RUYSSCHAERT

Director

Active
Lieve VANHOUTEGHEM

Director

Active

Ended mandates

Jan RUYSSCHAERT

Manager

Ended
Lieve VANHOUTEGHEM

Manager

Ended

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Mandates20/06/2024
    WIJZIGING RECHTSVORM - BENAMING - ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates30/09/2014
    KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN - WIJZIGING RECHTSVORM
    PDF
  • Restructuring07/03/2011
    ONTSLAGEN - BENOEMINGEN - RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
    PDF
  • Restructuring17/01/2011
    RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
    PDF
  • Mandates16/07/2010
    ONTSLAGEN - BENOEMINGEN - WIJZIGING RECHTSVORM
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 2025197,4 k €↑
  2. 2024
    Annual accounts 2024161,8 k €↓
  3. 2024
    Name changeCLINICAL ENGINEERING & RESEARCH
  4. 2013
    Annual accounts 2013261,5 k €↑
  5. 2012
    Annual accounts 201262,2 k €↓
  6. 2011
    Annual accounts 2011333,5 k €↑
  7. 2010
    Annual accounts 2010-659,9 k €↓
  8. 2009
    Annual accounts 2009-438,2 k €↑
  9. 2008
    Annual accounts 2008-552,4 k €↓
  10. 2007
    Annual accounts 2007152 k €↓
  11. 2006
    Annual accounts 2006152,7 k €
  12. 2006
    Name changeC.E.R. - Clinical Engineering and Research
  13. 20/12/1983
    IncorporationPrivate limited company